Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 4

1.

Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: a report on toxicity and efficacy from a prospective pilot phase II study.

Dharmarajan KV, Wexler LH, Wolden SL.

Pediatr Blood Cancer. 2013 Feb;60(2):242-7. doi: 10.1002/pbc.24205. Epub 2012 May 22.

PMID:
22619050
2.
3.

Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

Raney RB, Anderson JR, Barr FG, Donaldson SS, Pappo AS, Qualman SJ, Wiener ES, Maurer HM, Crist WM.

J Pediatr Hematol Oncol. 2001 May;23(4):215-20. Review.

PMID:
11846299
4.

Phase I. Trial of irinotecan plus carboplatin in two dose schedules.

Jones SF, Burris HA 3rd, Hainsworth JD, Yardley DA, Raefsky EA, Miranda FT, Kuzur ME, Willcutt NT, White MB, Greco FA.

Oncology (Williston Park). 2003 May;17(5 Suppl 5):36-40. Review.

PMID:
12800605

Supplemental Content

Support Center